Is PSA Still the Best Marker in Diagnosis and Monitoring of Prostate Cancer?
Alpaslan Akbaş 1 * , Mohamed Ismat Abdulmajed 2, Murat Tolga Gülpınar 1, Eyüp Burak Sancak 1
More Detail
1 Çanakkale Onsekiz Mart University, Faculty of Medicine, Department of Urology 17100 Çanakkale,Turkey2 Wrexham Maelor Hospital, Betsi Cadwaladr University Health Board, Department of Urology, Wrexham, UK* Corresponding Author

Abstract

Prostate cancer is the second most common cancer in males. At an early stage, prostate cancer barely causes any symptoms. The presence of symptoms upon presentation usually implies the presence of locally-advanced or metastatic disease. Therefore, early detection of prostate cancer is a necessity. Serum Prostate-Specific Antigen (PSA) test and Digital Rectal Examination (DRE) are used for early detection by the urologist. However serum PSA level is not only affected by the tumours but also other factors. The limitations of serum PSA test led to the introduction and application of various PSA derivatives to improve test sensitivity and specificity. In this review article, we provide a literature review and analysis of the currently available PSA test and its derivatives compared to new and developing potential tumour markers for detection and monitoring of prostate cancer.

License

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article Type: Review Article

EUR J GEN MED, Volume 12, Issue 2, April 2015, 187-193

https://doi.org/10.15197/sabad.1.12.40

Publication date: 15 Apr 2015

Article Views: 2036

Article Downloads: 1072

Open Access References How to cite this article